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Temporary portal vein embolization as a starter of liver regenerationq
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7 Denis Diderot, 100 Bd General Leclerc, 92110 Clichy, FranceSee Article, pages 354–362Preoperative portal vein embolization (PVE) has
been used clinically to induce hypertrophy of the contra-
lateral lobe and prevent postoperative life-threatening
liver failure as a result of anticipated insuﬃcient future
liver remnant (FLR) volume following resection.
Liver regeneration, which is the characteristic of this
parenchyma, is not possible without an adequate portal
ﬂow. In 1920, Rous and Larimore [1] discovered that
ligation of the portal vein branch of rabbits could con-
tribute to the atrophy of pathological lobe and hyper-
plasia of non-pathological one. Later, clinical studies
reported that portal vein occlusion secondary to tumor
invasion or ligation leads to atrophy of the ipsilateral
liver and hypertrophy of the contralateral liver. In
1990, Makuuchi et al. [2] found that if the portal vein
of one lobe is embolized by tumor thrombi, hypertrophy
of the contralateral lobe of the liver occurs resulting in
better tolerance of hepatectomy. These ﬁndings have
led to the use of preoperative PVE prior to extensive
liver hepatic resection. Although, there are few prospec-
tive or randomized trials examining the eﬀectiveness of
PVE on liver regeneration or its impact on liver resec-
tion, a recent meta-analysis, comprising 1088 patients
from 37 published series, conﬁrms that PVE is a safe
and eﬀective procedure in inducing liver hypertrophy0168-8278/$34.00  2008 European Association for the Study of the Liver.
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liver remnant [3,4].
Therefore, the ﬁrst target of liver teams was to ﬁnd
embolization agents which could induce permanent
embolization of the portal vein and its branches with
minimal risk of recanalization. These permanent agents
include synthetic glue (cyanoacrylate), synthetic emboli-
zation particles (polyvinyl alcohol), coils, iodized oil,
and absolute ethanol. Drawbacks of these permanent
agents are: (a) risk of extension of portal thrombosis
in patients with reduced hepatopetal portal ﬂow, as it
is commonly seen in patients with chronic liver disease;
(b) periportal inﬂammatory ﬁbrosis of the perivascular
connective tissue which may lead to diﬃculty with hilar
dissection; (c) migration of embolized material into por-
tal branches and (d) partial liver parenchymal necrosis
when absolute ethanol is used [5]. Absorbable biomate-
rials including absorbable gelatin sponge (gelfoam) par-
ticles with thrombin and ﬁbrin glue allow recanalization,
a theoretical drawback associated with these substances.
Conversely, unwarranted outcomes induced by migra-
tion of embolization materials into portal branches of
the contralateral lobe are minimal or absent. All of these
agents reportedly yield a similar extent of hypertrophy
in the FLR, 2–4 weeks after PVE and there is no general
consensus regarding the ideal embolization agent to be
used for PVE.
In the past, gelfoam has been considered to be less
eﬃcient than synthetic agents like cyanoacrylate to
induce liver hypertrophy. De Baere et al. [6] reported
that cyanoacrylate embolization produces a 69%
increase in volume of the FLR after 30 days compared
with a 53% increase in volume after 43 days in cases
where gelatin and thrombin were used. Huang et al.Published by Elsevier B.V. All rights reserved.
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nol as portal vein embolization agents to induce hyper-
trophy of the FLR in dogs. They concluded that
gelfoam alone was ineﬃcient to induce compensatory
liver hypertrophy. However, in both studies, gelfoam
embolization was performed with gelfoam sponge cut
in strips measuring 20  2 mm or 10  1 mm. In the
present study, authors used gelfoam powder which is
supposed to clog more distal branches of the portal vein
bed than strips, resulting in more complete and immedi-
ate obstruction.
Another way to induce hypertrophy of the liver is to
perform a portal vein ligation (PVL) on the side of the
future resected liver during the ﬁrst stage of a two-step
liver resection for bilobar hepatic lesions. Extraparen-
chymal ligation of the portal branch is performed using
a nonabsorbable suture. We recently showed that right
PVL is as eﬃcient as right PVE to induce hypertrophy
of the left liver remnant [8]. Interestingly, all PVL
patients had a revascularization of the right portal vas-
cular bed due to porto-portal shunts on the 4-week vol-
umetric CT-scan. This observation supports the idea
that temporary portal vein occlusion is enough to start
liver regeneration.
The article by Lainas at al. [9] challanges the old con-
cept of deﬁnitive and total occlusion of the portal vein
bed to induce an eﬃcient hypertrophy of the non-embol-
ized liver lobe. These new insights are in favor of a less
mechanistic concept of PVE. In this experimental study,
the authors’ aim was to assess the eﬀect of reversible PVE
by powdered absorbable gelfoam (Curaspon, Curamed-
ical, Zwaneburg, The Netherlands) on liver regeneration
in a pre-clinical model using monkeys. Liver regenera-
tion was assessed by BrdU incorporation and CT-scan
liver volume measurements, and portal recanalization
by repeated portograms. After reversible embolization,
complete portal vein revascularization occurred within
13 days, on average. It induced a signiﬁcant increase of
hepatocyte proliferation and a signiﬁcant hypertrophy
of liver volume in the non-embolized lobes. They con-
cluded that reversible PVE induces eﬃcient liver regener-
ation and avoids long-term liver scarring.
There are two main advantages to using powered gel-
foam as an embolization agent. First, an unwarranted
migration of the embolization agent in the non-embol-
ized lobe would not preclude liver regeneration as
described in one case in this study. Second, the complete
revascularisation of the vascular bed 2 weeks after
embolization would minimize injury of the embolized
liver if not ﬁnally resected. Two issues must be noted
in this study. The main issue is the lack of control group
receiving saline instead of gelfoam. This bias has been
worked around using each animal as its own control
for liver volume assessment and BrdU incorporation
using biopsies of the embolized lobes as control. Then,
it would have been of interest to compare the resultsof reversible PVE with deﬁnitive PVE group using cya-
noacrylate. It must be said in the authors’ defense that
experimentation in large animal models is cumbersome
and expensive.
The data from Lainas et al. [9] support that an initial
occlusion of the portal branch, even if not permanent, is
suﬃcient to start the mechanisms of liver regeneration in
the contralateral lobe. This new concept was already
suggested by the eﬃcacy of PVL despite recanalization
of the portal bed after ligation. The early recanalization
of the embolized portal territory within about 2 weeks
does not preclude the increase of liver volume. This is
consistent with the kinetic of liver hypertrophy after
portal occlusion consisting of quick initial liver hyper-
trophy within 2–3 weeks before reaching a ‘‘plateau”
period [10]. At the end of this initial period, the non-
embolized liver already reaches more than 75% of its
hypertrophy. Asian hepatic surgeons had already antic-
ipated these results and do not hesitate to perform major
liver resection 3 weeks after PVE.
The beauty of the reversible PVE is both the short-
term liver regeneration and the potential preservation
of the embolized liver which may lead to great impor-
tance in clinical practice. If embolized liver recovers after
recanalization, at least three clinical outcomes would be
expected. First, reversible PVE would increase the possi-
bilities of multi-step strategies in the surgical treatment
of malignant bilobar tumours like colorectal metastases,
in order to spare non tumoral liver parenchyma. Second,
in the ﬁeld of the basic research topic of the authors,
reversible PVE would help to improve hepatocyte trans-
plantation by providing a temporary window to improve
the yield of hepatocyte engraftment in recipient liver.
Finally, in living donor liver transplantation, why should
it not be expected that reversible right PVE would allow
hypertrophy of the future left liver graft in saving the
right liver in the donor? Although, the functional recov-
ery of the embolized liver after recanalization was not
proven, the authors open a new ﬁeld of future experi-
mental research to investigate this hypothesis.
Taken together, the data from Lainas et al. [9] pro-
vide new arguments suggesting that PVE-induced liver
hypertrophy is not only a matter of deﬁnitive vessels
occlusion but is probably dependant on many others
factors which remain to be understood. This paper
opens up new perspectives in the ﬁeld of preoperative
liver regeneration and preoperative portal ﬂow modula-
tion before liver resection in order to save liver paren-
chyma. The authors must be congratulated for that.
References
[1] Rous P, Larimore L. Relation of the portal ﬂow to liver
maintenance: a demonstration of liver atrophy conditional on
compensation. J Exp Med 1920;31:609–632.
[2] Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T,
Gunven P, et al. Preoperative portal embolization to increase
M. Lesurtel, J. Belghiti / Journal of Hepatology 49 (2008) 313–315 315safety of major hepatectomy for hilar bile duct carcinoma: a
preliminary report. Surgery 1990;107:521–527.
[3] Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R,
Vilgrain V, et al. Portal vein embolization before right hepatec-
tomy: prospective clinical trial. Ann Surg 2003;237:208–217.
[4] Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson
J, et al. Preoperative portal vein embolization for major liver
resection: a meta-analysis. Ann Surg 2008;247:49–57.
[5] Madoﬀ DC, Abdalla EK, Vauthey JN. Portal vein embolization in
preparation for major hepatic resection: evolution of a new
standard of care. J Vasc Interv Radiol 2005;16:779–790.
[6] de Baere T, Roche A, Vavasseur D, Therasse E, Indushekar S,
Elias D, et al. Portal vein embolization: utility for inducing left
hepatic lobe hypertrophy before surgery. Radiology
1993;188:73–77.[7] Huang JY, Yang WZ, Li JJ, Jiang N, Zheng QB. Portal vein
embolization induces compensatory hypertrophy of remnant liver.
World J Gastroenterol 2006;12:408–414.
[8] Aussilhou B, Lesurtel M, Sauvanet A, Farges O, Dokmak S,
Goasguen N, et al. Right portal vein ligation is as eﬃcient as
portal vein embolization to induce hypertrophy of the left liver
remnant. J Gastrointest Surg 2008;12:297–303.
[9] Lainas P, Boudechiche L, Osorio A, Coulomb A, Weber A,
Pariente D, et al. Liver regeneration and recanalization time
course following reversible portal vein embolization. J Hepatol
2008;49:354–362.
[10] Ribero D, Abdalla EK, Madoﬀ DC, Donadon M, Loyer EM,
Vauthey JN. Portal vein embolization before major hepatectomy
and its eﬀects on regeneration, resectability and outcome. Br J
Surg 2007;94:1386–1394.
